96 related articles for article (PubMed ID: 18069261)
1. [Molecular pathogenesis of myeloma for the therapeutic targets].
Hanamura I
Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
[TBL] [Abstract][Full Text] [Related]
2. Gene mutation revelation points to new target for myeloma treatment, studies say.
Garber K
J Natl Cancer Inst; 2007 Sep; 99(18):1362-4. PubMed ID: 17848662
[No Abstract] [Full Text] [Related]
3. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma).
Nuñez C; Cansino JR; Bethencourt F; Pérez-Utrilla M; Fraile B; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
Histopathology; 2008 Aug; 53(2):166-76. PubMed ID: 18752500
[TBL] [Abstract][Full Text] [Related]
4. The role of nuclear factor kappaB on angiogenesis regulation through monocyte chemotactic protein-1 in myeloma.
Stifter S
Med Hypotheses; 2006; 66(2):384-6. PubMed ID: 16253428
[TBL] [Abstract][Full Text] [Related]
5. The kinase NIK as a therapeutic target in multiple myeloma.
Gardam S; Beyaert R
Expert Opin Ther Targets; 2011 Feb; 15(2):207-18. PubMed ID: 21204728
[TBL] [Abstract][Full Text] [Related]
6. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
7. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.
Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR
Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955
[TBL] [Abstract][Full Text] [Related]
8. Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.
Fan S; Meng Q; Laterra JJ; Rosen EM
Oncogene; 2007 Jul; 26(33):4774-96. PubMed ID: 17297451
[TBL] [Abstract][Full Text] [Related]
9. NF-kappaB-related genetic diseases.
Courtois G; Smahi A
Cell Death Differ; 2006 May; 13(5):843-51. PubMed ID: 16397577
[TBL] [Abstract][Full Text] [Related]
10. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma.
Jackson-Bernitsas DG; Ichikawa H; Takada Y; Myers JN; Lin XL; Darnay BG; Chaturvedi MM; Aggarwal BB
Oncogene; 2007 Mar; 26(10):1385-97. PubMed ID: 16953224
[TBL] [Abstract][Full Text] [Related]
11. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
12. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production.
Chiron D; Pellat-Deceunynck C; Amiot M; Bataille R; Jego G
J Immunol; 2009 Apr; 182(7):4471-8. PubMed ID: 19299748
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.
Xu Y; Zhao Y; Huang H; Chen G; Wu X; Wang Y; Chang W; Zhu Z; Feng Y; Wu D
Br J Haematol; 2010 Sep; 150(5):543-53. PubMed ID: 20629663
[TBL] [Abstract][Full Text] [Related]
14. Regulation of NF-kB in multiple myeloma: therapeutic implications.
Feinman R; Siegel DS; Berenson J
Clin Adv Hematol Oncol; 2004 Mar; 2(3):162-6. PubMed ID: 16166946
[TBL] [Abstract][Full Text] [Related]
15. TNF receptor-associated factor 1 is a positive regulator of the NF-kappaB alternative pathway.
Lavorgna A; De Filippi R; Formisano S; Leonardi A
Mol Immunol; 2009 Oct; 46(16):3278-82. PubMed ID: 19698991
[TBL] [Abstract][Full Text] [Related]
16. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
17. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
18. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma: lusting for NF-kappaB.
Gilmore TD
Cancer Cell; 2007 Aug; 12(2):95-7. PubMed ID: 17692798
[TBL] [Abstract][Full Text] [Related]
20. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
Vrábel D; Pour L; Ševčíková S
Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
